A Novel Blood-Based RNA Assay for Early Detection of Lethal Prostate Cancers

Abstract

The proposed study illustrates the development of an entirely new class of non-invasive testin prostate cancer (PCa) that may address limitations of currently used methods (e.g. serumPSA testing, Gleason grading system) by bringing the power of RNA-based analysis to bloodtesting. Using the novel Prostate Cancer Classification System (PCS) developed by ourcollaborator, Dr. Michael Freeman, we can categorize PCas into subtypes that are related tosurvival, response to therapy and may even predict resistance to certain types of treatment.This RNA-based signature has been quantified in circulating tumor cells (CTCs) utilizing thenanostructure-embedded Thermoresponsive-NanoVelcro assay. By combining advances innanotechnology and genomics, this CTC-PCS assay would allow for dynamic resolution oftranscriptomic alterations over time providing new insights into dynamic cancer biology.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2020
Accession Number
AD1128660

Entities

People

  • Jasmine Wang

Organizations

  • Cedars-Sinai Medical Center

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Androgen Receptors
  • Androgens
  • Biomedical Research
  • Blood
  • Blood Substitutes
  • Calibration
  • Cancer
  • Cell Line
  • Cells
  • Classification
  • Data Analysis
  • Detection
  • Gene Expression
  • Information Science
  • Medical Personnel
  • Nanotechnology
  • Neoplasms
  • Oncology
  • Prostate
  • Prostate Cancer
  • Resistance
  • Survival
  • Therapy
  • Tissues

Fields of Study

  • Biology

Readers

  • Oncology and Biomarker-Based Cancer Detection.
  • Prostate Cancer Biology.